Global research and consulting firm Everest Group has named Indegene a leader in its Life Sciences AI and Analytics Services for Commercial PEAK Matrix Assessment 2025.

The firm acknowledged Indegene’s wide-ranging AI and analytics solutions across the life sciences commercial function.

It also commended Indegene’s continued efforts to embed Generative AI (GenAI) and Agentic AI capabilities across its commercial solutions portfolio, including investments in conversational AI, content summarisation engines, and multi-agent orchestration frameworks to drive intelligent, contextualised automation.

The report highlighted Indegene’s unique ability to combine its AI and Analytics capabilities with deep domain knowledge to deliver contextualised commercial solutions across a broad portfolio of therapy areas, including specifically tailored solutions for emerging therapy areas such as specialty care, oncology and rare diseases.

Commenting on the evolving industry landscape, Durga Ambati, Practice Director at Everest Group, said, “The growing emphasis on patient - and HCP-centricity to deliver superior customer experiences has modernised commercialisation strategies, placing data, analytics, and AI at the core of life sciences enterprises' go-to-market efforts. As a result, they are turning to strategic partners with domain-led digital expertise and scalable technology solutions to navigate the evolving landscape.”

 “Indegene’s broad portfolio of solutions within its NEXT platform, as well as its continued investments in embedding GenAI and Agentic AI across its capabilities, are well-complemented by its diverse therapeutic knowledge and strong market-facing assets. These factors have led to Indegene earning a leader position in Everest Group’s Life Sciences AI and Analytics Services for Commercial PEAK Matrix Assessment 2025,” she added.

Everest Group assessed 30 service providers on their AI and Analytics vision, capabilities, and market impact. The evaluation criteria included vision and strategy, scope of services, innovation and investments, delivery footprint, market adoption, portfolio mix, and client value delivered. 

Vivek Ghai, EVP-Enterprise Commercial Solutions at Indegene welcomed the recognition, stating, “Everest Group’s recognition validates our ability to translate advanced AI into real-world value for our clients.”

“Advancements in AI and analytics are enabling life sciences companies to modernize and transform their business operations with an AI-first, data-driven approach. Our focus is on helping clients scale AI responsibly - prioritizing use cases that drive measurable outcomes, integrating seamlessly with enterprise ecosystems, and delivering solutions that are not just innovative, but production-ready from day one,” he noted.

Indegene’s client base includes the world’s top 20 biopharma companies, along with many emerging biotech firms, and medical device companies. The company operates through 9 global hubs and maintains a presence in 19 offices across North America, Europe, and Asia.